NCT04408989View on ClinicalTrials.gov

A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and US Licensed-Avastin®.

PHASE1CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

January 11, 2021

Primary Completion Date

August 20, 2021

Study Completion Date

September 2, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

MB02-SP

Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion

DRUG

MB02-DM

Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion

DRUG

US licenced Avastin®

Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion

Trial Locations (2)

1010

Auckland Clinical Studies, Auckland

8011

Christchurch Clinical Studies Trust, Christchurch

All Listed Sponsors
lead

mAbxience Research S.L.

INDUSTRY

NCT04408989 - A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and US Licensed-Avastin®. | Biotech Hunter | Biotech Hunter